Abstract
Forty-five patients with relapsed or refractory multiple myeloma received continuous infusions of vincristine (0.4 mg total dose daily for 4 days) and adriamycin (9 mg m-2 daily for 4 days) with a high dose of methylprednisolone (1 g m-2 i.v. or p.o. daily by 1 h infusion), the VAMP regimen. Sixteen (36%) responded, with a median duration of remission of 11 months and median survival of 20 months. Major toxicities encountered were infective and cardiovascular. Two smaller groups of myeloma patients were treated with high dose methylprednisolone (HDMP) alone, or VAMP plus weekly low dose cyclophosphamide (Cyclo-VAMP). HDMP produced short responses in 25% of patients with less toxicity than VAMP. Cyclo-VAMP was used in a highly selected group of patients who had previously responded to high dose melphalan. It was well tolerated and produced responses in 61% of this group.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexanian R., Barlogie B., Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986 Jul;105(1):8–11. doi: 10.7326/0003-4819-105-1-8. [DOI] [PubMed] [Google Scholar]
- Alexanian R., Yap B. S., Bodey G. P. Prednisone pulse therapy for refractory myeloma. Blood. 1983 Sep;62(3):572–577. [PubMed] [Google Scholar]
- Anderson H., Scarffe J. H., Lambert M., Smith D. B., Chan C. C., Chadwick G., McMahon A., Chang J., Crowther D., Swindell R. VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol. 1987 Jul-Sep;5(3):213–222. doi: 10.1002/hon.2900050308. [DOI] [PubMed] [Google Scholar]
- Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984 May 24;310(21):1353–1356. doi: 10.1056/NEJM198405243102104. [DOI] [PubMed] [Google Scholar]
- Bonnet J., Alexanian R., Salmon S., Bottomley R., Amare M., Haut A., Dixon D. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer Treat Rep. 1982 Jun;66(6):1267–1271. [PubMed] [Google Scholar]
- Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
- Kyle R. A., Pajak T. F., Henderson E. S., Nawabi I. U., Brunner K., Henry P. H., McIntyre O. R., Holland J. F. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Cancer Treat Rep. 1982 Mar;66(3):451–456. [PubMed] [Google Scholar]